摘要
目的回顾性分析4种乳腺癌分子分型的临床特点,比较其在新辅助化疗方案中的疗效。方法回顾性分析本院初治并接受新辅助化疗的乳腺癌患者172例的病历资料。根据免疫组织化学结果,将乳腺癌患者分为4种亚型:Luminal A型、Luminal B型、Her-2过表达型和basal-like型。对不同亚型患者的临床资料进行分析,比较4种亚型乳腺癌患者在新辅助化疗中的疗效。结果 172例乳腺癌患者中,Luminal A型47.1%,Luminal B型23.8%,Her-2过表达型11.6%,Basal-like型16.3%;4种亚型的病理完全缓解率分别为11.1%、12.2%、35.0%、42.9%。Basal-like型病理完全缓解率明显高于Luminal A亚型和Luminal B亚型(P=0.012)。结论乳腺癌分子亚型可作为病理完全缓解的独立预测因子,为乳腺癌个体化治疗提供依据。
Objective The clinical characteristics of 4 breast cancer subtypes were analyzed retrospectively and their therapeutic effects of neoadjuvant chemotherapy were compared.Methods 172 cases of patients with breast cancer treated with neoadjuvant chemotherapy were included in this retrospective study.Molecular subtypes were categorized as Luminal A subtype,Luminal B subtype,HER-2 overexpression subtype and basal-like subtype,based on the immunohistochemistry results.The clinical data were analyzed and therapeutic effects of neoadjuvant chem-otherapy were compared in the 4 different types of breast cancer.Results Among all 172 cases,the proportion of Luminal A subtype was 47.1%,Luminal B subtype 23.8%,HER-2 overexpression subtype 11.6%,and basal-like subtype 16.3% respectively.The pathologic complete remission rates of the four subtypes were：11.1%,12.2%, 35.0% and 42.9%.The pathologic complete remission rate of patients with basal-like subtype was significantly higher than those of the patients with Luminal A subtype and Luminal B subtype （P =0.012）.Conclusion Four molecular subtypes of breast cancer could be the independent indicator of the pathologic complete remission and the basis for individualized treatment for breast cancer.
出处
《济宁医学院学报》
2015年第5期327-330,共4页
Journal of Jining Medical University
基金
济宁市科技局课题(编号:2012jnwk02
2013jnwk77)
山东省教育厅课题(编号:J13LK13)
关键词
乳腺癌
分子分型
新辅助化疗
临床特征
Breast cancer
Molecular subtype
Neoadjuvant chemotherapy
Clinical feature
